Associated tags: Nobel Prize, DSM-IV codes, Cell, Psychiatry, Therapy, Central nervous system, CNS, Pharmaceutical industry, Webcast, Conference
Locations: GQ, CA, SAN FRANCISCO, WARDWELL, NEW YORK, NY, US, NEEDHAM, NC
Retrieved on:
Wednesday, April 24, 2024
Sale,
Prospectus,
J.P. Morgan & Co.,
RBC Capital Markets,
Broadridge Financial Solutions,
Morgan Stanley,
Vesey Street,
Canaccord Genuity,
Security (finance),
SVB Securities,
Form S-3,
CNS,
Form,
Exercise,
Therapy,
Varick Street,
Equity capital markets,
Cantor,
2nd Floor,
State Street,
Central nervous system,
BofA Securities,
Attention,
Telephone,
File,
Needham & Company All of the shares in the public offering, including the full exercise of the underwriters’ option, were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $575 million, before deducting underwriting discounts and commissions and offering expenses.
Key Points:
- All of the shares in the public offering, including the full exercise of the underwriters’ option, were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $575 million, before deducting underwriting discounts and commissions and offering expenses.
- J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets acted as joint book-running managers for the offering.
- Cantor, Mizuho, Canaccord Genuity and Needham & Company acted as co-managers for the offering.
- The public offering was made pursuant to a shelf registration statement on Form S-3 (including a base prospectus) that was previously filed with the Securities and Exchange Commission (the “SEC”) and became effective upon filing.
Sale,
Prospectus,
J.P. Morgan & Co.,
RBC Capital Markets,
Broadridge Financial Solutions,
Morgan Stanley,
Vesey Street,
Canaccord Genuity,
Security (finance),
SVB Securities,
Form S-3,
CNS,
Form,
Therapy,
Varick Street,
Equity capital markets,
Cantor,
2nd Floor,
State Street,
Central nervous system,
BofA Securities,
Attention,
Telephone,
File,
Needham & Company NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
Key Points:
- NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
- All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $500.0 million before deducting underwriting discounts and commissions and offering expenses.
- Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,027,397 shares on the same terms and conditions.
- J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.
Sale,
Prospectus,
J.P. Morgan & Co.,
RBC Capital Markets,
Broadridge Financial Solutions,
Morgan Stanley,
Vesey Street,
Security (finance),
SVB Securities,
CNS,
Form,
Therapy,
Varick Street,
Equity capital markets,
2nd Floor,
State Street,
Central nervous system,
BofA Securities,
Attention,
Telephone,
File NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock.
Key Points:
- NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) (“Intra-Cellular Therapies”), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock.
- In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
- All of the shares in the offering will be sold by Intra-Cellular Therapies.
- J.P. Morgan, Leerink Partners, BofA Securities, Morgan Stanley and RBC Capital Markets are acting as joint book-running managers for the offering.
Key Points:
- ET
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
- Topline results from our second Phase 3 study, Study 502, are anticipated late in the second quarter of this year.
- In this study, lumateperone 42 mg robustly improved depressive symptoms as reported by patients as measured by the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR-16) (p
- “In this Phase 3 study, lumateperone demonstrated a robust effect as an adjunctive treatment to antidepressants in patients with MDD who had inadequate response to antidepressant therapy.
Growth,
Information technology,
Central nervous system,
General counsel,
Warner Chilcott,
CNS,
Senior,
Davis Polk,
Therapy,
Corporate development,
Management Mr. Halstead is currently serving as Executive Vice President and General Counsel.
Key Points:
- Mr. Halstead is currently serving as Executive Vice President and General Counsel.
- In this newly created leadership role, Mr. Halstead will oversee several functions within the Company including legal, human resources, manufacturing & supply chain, quality, compliance, information technology, and external innovation.
- “Michael is an exceptional leader who has been instrumental in Intra-Cellular Therapies’ strong growth over the last decade,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
- He joined Intra-Cellular Therapies in 2014 as Senior Vice President and General Counsel and was promoted to Executive Vice President and General Counsel in 2019.
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences:
Key Points:
- NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences:
A live and achieved webcast of the Company’s presentation at the Leerink Partners Global Biopharma Conference can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com.
- Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
Retrieved on:
Tuesday, February 27, 2024
NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m.
Key Points:
- NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m.
- ET in Boston, MA.
- The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com.
- Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
Retrieved on:
Thursday, February 22, 2024
NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter ended December 31, 2023 and provided a corporate update.
Key Points:
- In the fourth quarter, total prescriptions of CAPLYTA increased 55% over the same period in 2022, and 10% sequentially over the third quarter of 2023.
- As a result, we expect to report topline results from Study 501 in April of this year.
- In addition, we expect to report topline results from Study 502 late in the second quarter of this year.
- The Company will host a live conference call and webcast today at 8:30 AM Eastern Time to discuss the Company’s financial results and provide a corporate update.
Retrieved on:
Thursday, February 8, 2024
To attend the live conference call by phone please use this registration link .
Key Points:
- To attend the live conference call by phone please use this registration link .
- All participants must use the link to complete the online registration process in advance of the conference call.
- The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com .
- Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA.
Key Points:
- NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA.
- The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com.
- Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
